India, Nov. 21 -- image credit- pib
The Technology Development Board (TDB), Department of Science & Technology, Government of India, has sanctioned financial support to Mumbai-based startup TechInvention Lifecare for the establishment of a commercial-scale cGMP facility for the production of an indigenously developed 16-valent Pneumococcal Conjugate Vaccine (PCV-16).
The supported project aims to strengthen India's capability in next-generation conjugate vaccines and reduce long-term dependence on imported products through domestic innovation and manufacturing.
The PCV-16 technology is built on a strategically selected panel of 16 pneumococcal serotypes, representing strains most associated with invasive pneumococcal disease (IPD), ant...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.